DelveInsight’s, “Basal Cell Nevus Syndrome Pipeline Insight 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Basal Cell Nevus Syndrome pipeline landscape. It covers the Basal Cell Nevus Syndrome pipeline drug profiles, including Basal Cell Nevus Syndrome clinical trials and nonclinical stage products. It also covers the Basal Cell Nevus Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Basal Cell Nevus Syndrome Pipeline treatment landscape of the report, click here @ Basal Cell Nevus Syndrome Pipeline Outlook

 

Key Takeaways from the Basal Cell Nevus Syndrome Pipeline Report

• DelveInsight’s Basal Cell Nevus Syndrome Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Basal Cell Nevus Syndrome.
• The leading Basal Cell Nevus Syndrome Companies include Roche, PellePharm, Palvella Therapeutics, and Others
• Promising Basal Cell Nevus Syndrome Pipeline Therapies include Patidegib, Vismodegib, and others
• In the Basal Cell Nevus Syndrome Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Basal Cell Nevus Syndrome clinical trials studies, Basal Cell Nevus Syndrome NDA approvals (if any), and product development activities comprising the technology, Basal Cell Nevus Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
• The Basal Cell Nevus Syndrome companies and academics are working to assess challenges and seek opportunities that could influence Basal Cell Nevus Syndrome R&D. The Basal Cell Nevus Syndrome therapies under development are focused on novel approaches to treat/improve Basal Cell Nevus Syndrome.

 

For further information, refer to the detailed Basal Cell Nevus Syndrome Unmet Needs, Basal Cell Nevus Syndrome Market Drivers, and Basal Cell Nevus Syndrome Market Barriers, click here for Basal Cell Nevus Syndrome Ongoing Clinical Trial Analysis

 

Basal Cell Nevus Syndrome Overview

The nevoid basal cell carcinoma syndrome (NBCCS) is a rare, complex genetic disorder characterized by a wide variety of developmental abnormalities and a predisposition to developing certain forms of cancer, particularly a type of skin cancer known as basal cell carcinoma.

 

Request a sample and discover the recent advances in Basal Cell Nevus Syndrome Ongoing Clinical Trial Analysis and Medications, click here @ Basal Cell Nevus Syndrome Treatment Landscape

 

Basal Cell Nevus Syndrome Emerging Drugs

• Patidegib: PellePharm

PellePharm is focused on developing patidegib, an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. As of November 2018, PellePharm and LEO Pharma entered into a strategic collaboration to address the unmet medical needs for rare skin conditions, such as Gorlin Syndrome and High Frequency Basal Cell Carcinoma (HF-BCC). PellePharm has received both Orphan Drug Designation and Breakthrough Therapy Designation for Patidegib Topical Gel in Gorlin Syndrome from the FDA, as well as Orphan Drug Designation in Gorlin Syndrome from EMA’s Committee for Orphan Medicinal Products in the EU.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Basal cell nevus syndrome.

• Vismodegib: Roche

Vismodegib is an experimental, oral smoothened antagonist and thus inhibits hedgehog pathway. It is under Phase II development for Basal cell nevus syndrome.

 

Dive deep into rich insights for drugs for Basal Cell Nevus Syndrome Market Drivers and Basal Cell Nevus Syndrome Market Barriers, click here @ Basal Cell Nevus Syndrome Unmet Needs and Analyst Views

 

Basal Cell Nevus Syndrome Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for Basal Cell Carcinoma. The companies which have their Basal Cell Carcinoma drug candidates in the most advanced stage, i.e. Phase III include, PellePharm.

 

Scope of the Basal Cell Nevus Syndrome Pipeline Report

• Coverage- Global
• Basal Cell Nevus Syndrome Companies- Roche, PellePharm, Palvella Therapeutics, and Others
• Basal Cell Nevus Syndrome Pipeline Therapies- Patidegib, Vismodegib, and others
• Basal Cell Nevus Syndrome Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Basal Cell Nevus Syndrome Mergers and acquisitions, Basal Cell Nevus Syndrome Licensing Activities @ Basal Cell Nevus Syndrome Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. Basal Cell Nevus Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Patidegib: PellePharm
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Vismodegib: Roche
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Basal Cell Nevus Syndrome Key Companies
17. Basal Cell Nevus Syndrome Key Products
18. Basal Cell Nevus Syndrome- Unmet Needs
19. Basal Cell Nevus Syndrome- Market Drivers and Barriers
20. Basal Cell Nevus Syndrome- Future Perspectives and Conclusion
21. Basal Cell Nevus Syndrome Analyst Views
22. Basal Cell Nevus Syndrome Key Companies
23. Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services